How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.

IF 4.5 2区医学 Q1 HEMATOLOGY

Bone Marrow Transplantation Pub Date : 2025-04-14 DOI:10.1038/s41409-025-02599-x

Peter Dreger, Sairah Ahmed, Ali Bazarbachi, Sascha Dietrich, Timothy S Fenske, Nilanjan Ghosh, Olivier Hermine, Mehdi Hamadani

{"title":"How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.","authors":"Peter Dreger, Sairah Ahmed, Ali Bazarbachi, Sascha Dietrich, Timothy S Fenske, Nilanjan Ghosh, Olivier Hermine, Mehdi Hamadani","doi":"10.1038/s41409-025-02599-x","DOIUrl":null,"url":null,"abstract":"<p><p>Cellular therapies have been cornerstones of the treatment of mantle cell lymphoma (MCL) for decades and have helped to improve the outcome of this formerly very unfavourable B-cell lymphoma considerably. Current established roles of cellular therapies include autologous hematopoietic cell transplantation (HCT) as part of first-line therapy, chimeric antigen receptor-engineered T-cells (CART) for relapsed/refractory MCL, and allogeneic HCT for settings in which CARTs have failed or are unavailable. Therapeutic innovations have recently entered the MCL treatment landscape and are moving upstream in treatment algorithms, challenging the existing management principles. The purpose of this paper is to give some guidance regarding how to best use cellular therapies in this increasingly complex environment. Due to differences in CART labels, available non-cellular treatment options, and philosophy between the American and the European health systems, we found it reasonable to contrast the American and European perspectives on defined standard scenarios, which are often overlapping but show discrepancies in some important aspects.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone Marrow Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41409-025-02599-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Cellular therapies have been cornerstones of the treatment of mantle cell lymphoma (MCL) for decades and have helped to improve the outcome of this formerly very unfavourable B-cell lymphoma considerably. Current established roles of cellular therapies include autologous hematopoietic cell transplantation (HCT) as part of first-line therapy, chimeric antigen receptor-engineered T-cells (CART) for relapsed/refractory MCL, and allogeneic HCT for settings in which CARTs have failed or are unavailable. Therapeutic innovations have recently entered the MCL treatment landscape and are moving upstream in treatment algorithms, challenging the existing management principles. The purpose of this paper is to give some guidance regarding how to best use cellular therapies in this increasingly complex environment. Due to differences in CART labels, available non-cellular treatment options, and philosophy between the American and the European health systems, we found it reasonable to contrast the American and European perspectives on defined standard scenarios, which are often overlapping but show discrepancies in some important aspects.

查看原文本刊更多论文

2025年我们如何用细胞疗法治疗套细胞淋巴瘤：欧洲和美国的观点。

几十年来，细胞疗法一直是套细胞淋巴瘤（MCL）治疗的基石，并极大地改善了这种以前非常不利的b细胞淋巴瘤的预后。目前已确定的细胞疗法的作用包括自体造血细胞移植（HCT）作为一线治疗的一部分，嵌合抗原受体工程t细胞（CART）用于复发/难治性MCL，以及同种异体HCT用于CART失败或不可用的情况。治疗创新最近进入了MCL治疗领域，并在治疗算法上向上游移动，挑战了现有的管理原则。本文的目的是为如何在这种日益复杂的环境中最好地使用细胞疗法提供一些指导。由于美国和欧洲卫生系统在CART标签、可用的非细胞治疗方案和理念上的差异，我们发现对比美国和欧洲在定义标准方案上的观点是合理的，这些观点经常重叠，但在一些重要方面显示出差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone Marrow Transplantation 医学-免疫学

CiteScore

8.40

自引率

8.30%

发文量

337

审稿时长

6 months

期刊介绍： Bone Marrow Transplantation publishes high quality, peer reviewed original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation. The broad scope of the journal thus encompasses topics such as stem cell biology, e.g., kinetics and cytokine control, transplantation immunology e.g., HLA and matching techniques, translational research, and clinical results of specific transplant protocols. Bone Marrow Transplantation publishes 24 issues a year.